comparemela.com

Latest Breaking News On - உணர்ச்சி பல்கலைக்கழகம் வெற்றி புற்றுநோய் நிறுவனம் - Page 1 : comparemela.com

Radiation Speeds Up Biological Aging in Head and Neck Cancer

Kintara Therapeutics, Inc says VAL-083 treatment arm in the Phase 2/3 clinical trial for glioblastoma multiforme has now been activated in 15 US sites

Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma

Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma News provided by Share this article Share this article SAN DIEGO, May 26, 2021 /PRNewswire/  Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has been activated in 15 U.S. sites as of May 14, 2021.  The trial, titled GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), is a patient-centered, adaptive platform trial for registration evaluating multiple therapies for patients with newly-diagnosed and recurrent GBM. Since January 2021, GCAR has accelerated the pace of clinical site activation with increased awareness in the medical community of Kintara s arm of

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.